Objective: To investigate the in vivo oxidation of 13 C18X2n-6 and its conversion into longer-chain polyunsaturates (LCPs) in healthy subjects. Design: Blood samples were collected from six subjects before (fasted) and 7, 11 (non-fasted), 24, 48, 72, 168 and 336 h (fasted) after ingestion of a single bolus of 45 mg uniformly labeled 13 C18X2n-6 dissolved in 8 g olive oil. In three subjects, breath was also sampled and CO 2 production measured every hour during the ®rst 12 h. Subjects consumed their habitual diets. Plasma 13 C-enrichments were measured by GC-C-IRMS and fatty acid compositions by GCaFID. Setting: Maastricht University, Department of Human Biology. Subjects: Three men and three women, recruited by local advertisement. Results: The traceratracee ratio (TTR) of C18X2n-6 in plasma total lipids was already increased 5 h after tracer intake. The mean peak amount (AE s.e.m) of 13 C18X2n-6 (3.4AE 0.8 mg; 7.6% of dose) was found after about 17 h, 13 C18X3n-6 (0.018 AE 0.008 mg; 0.04% of dose) after 7 ± 48 h, and 13 C20X3n-6 (0.028 AE 0.011 mg; 0.06% of dose) after 48 ± 336 h. Time to peak TTRs of C20X4n-6 varied between subjects and were on average 0.022 AE 0.006 mg (0.05% of dose). The proportion of 13 C18X2n-6 recovered in breath after 12 h ranged between 16.8 and 25.1%. Conclusions: These ®ndings suggest that a single bolus of 45 mg U-13 C18X2n-6 can be used to study the oxidation of 13 C18X2n-6. However, because of the low TTRs for C20X4n-6, a higher dose is recommended for studying the conversion of 13 C18X2n-6 into LCPs. In addition, since only about 35% of the tracer was found in plasma total lipids and as 13 CO 2 in breath, it might be necessary to study other accessible lipid fractions as well to study the overall conversion of linoleic acid.
Introduction
Arachidonic acid (C20X4n-6) is a major precursor of eicosanoids, which have important physiological and pathological functions in humans such as in in¯ammatory processes, immunological reactions and platelet aggregation. Arachidonic acid can be derived from the diet, but can also be synthesized, mainly in the liver, by alternate desaturation and elongation of dietary linoleic acid (C18X2n-6). These conversion reactions, however, have been investigated mainly in in vitro and animal studies. To what extent linoleic acid is converted into its longer chain more unsaturated metabolites in man is only partially known.
A few studies have examined the in vivo metabolism of linoleic acid in humans. In 1967, Nichaman et al reported the in vivo oxidation and conversion of 14 C labelled linoleic acid into arachidonic acid in normo-and hyperlipidemic males (Nichaman et al, 1967) . More recently, the conversion of deuterated linoleic acid has been demonstrated in three human studies (Emken et al, 1994 (Emken et al, , 1998 (Emken et al, , 1999 . In these studies, however, large doses of deuterated linoleic acid were administered, which may have decreased the dietary n-3 to n-6 fatty acid ratio considerably. Because linoleic acid and alinolenic acid compete for the same D6 desaturase, high doses of labelled linoleic acid may have an unwanted impact on conversion reactions, and substrate inhibition may occur.
Other previous studies have used 13 C labelled linoleic acid to investigate in lactating women the appearance of n-6 fatty acids in milk and linoleic acid oxidation (Demmelmair et al, 1998) . Also, the conversion of 13 C linoleic acid has been studied in infants (Demmelmair et al, 1995; Carnielli et al, 1996; Salem, et al 1996; Sauerwald et al, 1996; Szitanyi et al, 1999) . How the results in these special groups compare to those of the general population is not known. In addition, previous studies did not combine the conversion and oxidation of 13 C linoleic acid. Therefore, the aim of this study is to examine both oxidation of 13 C linoleic acid and its conversion into longer chain polyunsaturated fatty acids in normal healthy adults. ). None of the subjects used medication known to affect lipid metabolism. All subjects were apparently healthy, as indicated by a general questionnaire. Three of the participants smoked, one man and two women. Furthermore, two women used oral contraceptives. The protocol had been approved by the local ethical committee and all subjects gave their written informed consent. The study was performed during the summer of 1996.
Subjects and methods

Subjects
Experimental design
After an overnight fast, subjects came to the department at 8.00 am First, a blood sample of 10 ml was collected. Thereafter, the CO 2 production of three subjects was measured by indirect calorimetry (Sensormedics 2900; Sensormedics, Anaheim, CA, USA or Oxycon b; Mijnhardt, The Netherlands), after which a breath sample was taken. Breath samples were stored in vacutainers (Becton & Dickinson, Meylan, France). All six subjects then received a single bolus of uniformly labelled 13 C-linoleic acid (isotopic purity b98% 13 C18X2n-6, chemical purity b95%; Martek Biosciences Corporation, Columbia, MD) as methylester at a dosage of 45 mg dissolved in 8 g olive oil. Blood samples were collected every 2 h, and breath samples (three subjects) hourly during the ®rst 12 h. Further fasting blood samples and breath samples (three subjects) were collected after 24, 48, 72, 96 and 168 h, and after 336 h a ®nal blood sample was collected.
Two hours after receiving the 13 C-linoleic acid, subjects were allowed to eat breakfast ad libitum. During the ®rst day, they stayed at the department and food, which subjects might consume ad libitum, was available for the whole day. Use of caffeine or drinks containing caffeine was prohibited during the ®rst day only, because of the possible stimulating effect of caffeine on lipolysis and lipid oxidation (Astrup et al, 1990) .
Blood sampling and analysis
Until 12 h after 13 C18X2n-6 administration, blood was sampled in an EDTA-containing tube through a Te¯on catheter (Baxter Quick Cath, Dupont, Ireland) or in a vacuum tube using a 1.2 mm needle (Strauss Kanule; Luer, Wa Èchtersbach, Germany) with the volunteer in a recumbent position. Subjects were free to choose the method of sampling. The catheter was¯ushed every hour with 1 ml of a heparin solution (0.5 IU heparin-sodium; Leo Pharmaceutical Products BV, Weesp, The Netherlands). The other fasting blood samples were taken with a vacuum tube. Plasma for 13 C enrichment analyses and analyses of fatty acid composition of plasma total lipids was obtained by centrifugation at 2000 g for 15 min at 4 C, within 1 h of venipuncture. Plasma samples were quickly snap-frozen and stored at À80 C. Lipids from plasma were extracted (Folch et al, 1957) , using tri-heptadecanoic acid (17X0) as an internal standard. Thereafter, lipid extracts were hydrolyzed and the resulting fatty acid methylated (Lepage & Roy, 1986) . The absolute fatty acid composition in plasma total lipids was analyzed using a gas chromatograph with a¯ame ionization detector (GCaFID, Perkin Elmer, Norwalk, Connecticut, USA) as described before (Vermunt et al, 2000) .
13
C enrichments of individual FAMEs in total lipids from plasma and in breath were analyzed with a gas chromatograph (Varian 3400) coupled with an isotope ratio mass spectrometer (GC-C-IRMS; Finnigan MAT 252, Bremen, Germany) via a combustion interface. Samples were injected on a 50 m column (BPX70, 0.33 mm, 0.25 mm ®lm thickness; SGE, Austin, Texas, USA) at a temperature of 250 C. Helium gas was used as a carrier (injector inlet pressure 124 kPa). Enrichments of 18X2n-6, 18X3n-6, 20X3n-6, 20X4n-6, 22X4n-6 and 22X5n-6 were determined in one run. The GC-oven was programmed at 160 C for 10 min (rise of 1 Camin), then 190 C for 14 min (rise of 30 Camin), and ®nally 260 C for 25 min.
Calculations
The difference between the traceratracee ratio (TTR;
13 Ca 12 C ratio) of the individual FAMEs and a known reference standard was expressed as the delta (d 13 C). The true TTR of the FAME was then calculated by normalizing the isotopic enrichment (d 13 C) against the international standard Pee Dee Belemate limestone (PDB), which has a TTR of 0.0112372. The concentration of a 13 C labelled fatty acid was calculated with the true TTR and the plasma concentration of that particular fatty acid. It was assumed that during fatty acid elongation the two carbon-atom fragments added after elongation were not enriched above background. Absolute amounts (in mg) of fatty acids were calculated based on a plasma volume of 4.5% of body weight (Gregersen & Rawson, 1959) .
Recovery of 13 C in breath derived from 13 C18X2n-6 during the ®rst 12 h after tracer intake was calculated from the TTR in breath and the absolute CO 2 production.
Values of subjects were averaged, and presented as means AE standard errors.
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Results
On the basis of the ®rst three subjects, whose results are presented in Figure 1 , it was decided to measure the 13 C enrichments of LCPs in plasma total lipids only at t 0, 7 (plasma of t 6 and t 8 h pooled), 11 (plasma of t 10 h and t 12 h pooled), 24, 48, 72, 168 and 336 h for the other three subjects so as to reduce the number of analyses to a more manageable number. In order to compare the results of the ®rst three subjects with the others, the data from t 6 h and t 8 h and from t 10 h and t 12 h were averaged.
Traceratracee ratios
Peak traceratracee ratios (TTR) of C18X2n-6 in plasma total lipids were obtained within the ®rst 12 h for ®ve subjects and after 48 h for one subject, with a mean of 107.8Â10 À5 AE 22.6Â10 À5 after 17 h (Table 1) . Mean peak TTR was the highest for C18X2n-6. Peak TTRs of C18X3n-6 were reached after 7 ± 48 h, with a mean of 46.3Â10 À5 AE 16.9Â10
À5 after 25 h. Peak TTRs of C20X3n-6 were reached after 48 ± 72 h for ®ve subjects and after 336 h for one subject, and was on average 16.3Â10 À5 AE 5.0Â10 À5 . Time to peak TTRs of C20X4n-6 varied between the subjects and were rather low. TTRs of C22X4n-6 and C22X5n-6 were very low as well, and TTRs exceeding background enrichments were observed in three subjects only.
Plasma fatty acid concentrations
Mean fasted n-6 fatty acid concentrations in plasma total lipids were the highest for C18X2n-6 (953 AE 52 mgal; 32.54 AE 1.12% of total fatty acids) and C20X4n-6 (195 AE 10 mgal; 6.73 AE 0.40% of total fatty acids). Mean fasted plasma concentrations were 9.3 AE 1.4 mgal (0.31 AE 0.02% of total fatty acids) for C18X3n-6. 44.0 AE 3.0 mgal (1.50 AE 0.09% of total fatty acids) for C20X3n-6, 6.3 AE 0.2 mgal (0.22 AE 0.01% of total fatty acids) for C22X4n-6, and 6.9 AE 0.5 mgal (0.24 AE 0.03% of total fatty acids) for C22X5n-6. C18X2n-6 started to increase almost directly after tracer intake (Figure 2) . After 168 h most of the 13 C18X2n-6 had disappeared from the plasma, but only after 336 h had values nearly returned to baseline. Appearance of 13 C18X3n-6 in the plasma occurred almost at the same time as that of 13 C18X2n-6. At the end of the study, plasma levels of 13 C18X3n-6 had almost returned to baseline. The mean amount of plasma 13 C20X3n-6 increased slowly over time until after 72 h, whereafter it declined. After 336 h, most subjects had still considerable amounts of 13 C20X3n-6 in plasma as compared to their peak.
13
C20X4n-6 appeared rather quickly in plasma and continued to increase until after 336 hours. Amounts of 13 C22X4n-6 and 13
C22X5n-6 were very small, and are, therefore, not shown in Figure 2 .
The mean peak absolute amount of 13 C18X2n-6 in plasma was 3.4 AE 0.8 mg, which was 7.6% of the tracer dose (Figure 3) . Peak amounts of 13 C18X3n-6 were 0.003 ± 0.057 mg, with a mean amount of 0.018 AE 0.008 mg. The mean peak amount of 13 C20X3n-6 was 0.028 AE 0.011 mg, which was only about 0.06% of the tracer dose. The peak C20X4n-6 after a single dose of 13 C18X2n-6 during the course of the study. Values were calculated based on a plasma volume of 4.5% of body weight (Gregersen & Rawson, 1959) . Figure 3 Individual (S1 ± S6) and mean peak amounts (in mg) of plasma 13 C18X2n-6, 13 C18X3n-6, 13 C20X3n-6 and 13 C20X4n-6 after a single dose of 13 C18X2n-6. Values were calculated based on a plasma volume of 4.5% of subjects body weight (Gregersen & Rawson, 1959) . 13 C20X3n-6 13 C20X4n-6) was 0.15% of the tracer dose and 2.0% of the peak amount of 13 C18X2n-6.
Oxidation
Breath samples were measured in 3 subjects. Peaks in 13 C enrichment in breath were reached after 3 ± 5 h and ranged from 7 ± 12% (data not shown). Figure 4 shows the recovery of 13 C in breath derived from 13
C18X2n-6 at various time points during the ®rst 12 h after tracer intake. After 6 h, total 13 C recovery ranged between 11.9 and 17.4% while after 12 h total recovery of the tracer was increased to 16.8 ± 25.1%.
Discussion
This study demonstrates that conversion of 13 C18X2n-6 into 13 C18X3n-6 starts almost immediately after tracer intake. The peak TTR of 13 C18X3n-6 was much higher than that of 13 C20X3n-6. However, because of the smaller pool of plasma C18X3n-6 relative to C20X3n-6, absolute peak amounts of 13 C18X3n-6 were lower than those of 13 C20X3n-6. The small pool of C18X3n-6 may be due to the rapid elongation step of C18X3n-6, into C20X3n-6, as suggested from rat studies (Bernert & Sprecher, 1975) . From animal studies using radioactive isotopes, it is known that C20X4n-6 can be converted into C22X4n-6 and C22X5n-6 (Bernert & Sprecher, 1975; Mohammed et al, 1995) . However, we hardly found any 13 C enrichment in plasma of these latter two fatty acids. This is in agreement with results of Emken et al, (1994 Emken et al, ( , 1998 . These ®ndings may be due to the preferential b-oxidation of C22X4n-6 rather than esteri®cation, and the preferential esteri®cation of C20X4n-6 rather than b-oxidation (Verdino et al, 1964; Sprecher, 1967; Sprecher et al, 1995) . In addition, the failure to ®nd measurable amounts of C22X5n-6 may have been caused by the very slow rate of desaturation of C22X4n-6 into C22X5n-6 as found for rats (Bernert & Sprecher, 1975) .
Mean time to peak TTR was 17 h for C18X2n-6, and 104 h for C20X3n-6. The mean peaks of these fatty acids, however, were both affected by one extreme value from different subjects. Without these outliers, mean time to peak TTRs were 10 and 58 h. Peak 13 C enrichment of C18X2n-6 in milk of lactating women was reached 12 h after ingestion of 1 mg 13 C linoleic acidakg body weight (Demmelmair et al, 1998) , which corresponds with our plasma results. Time to peak 13 C enrichment of C20X3n-6 was 12 ± 24 h in milk of lactating women (Demmelmair et al, 1998) . Thus, 13 C18X2n-6 seems to appear at the same time in plasma and human milk, while the peak in 13 C20X3n-6 was reached earlier in human milk (Demmelmair et al, 1998 ) as compared to plasma. Appearance of the 13 C labelled fatty acids in plasma of lactating women, which is not investigated in the study of Demmelmair et al (1998) , may however be different from that of non-lactating subjects.
Peak 13 C enrichments in breath were obtained 3 ± 5 h after intake of the labelled linoleic acid, which agree well with the time to peak 13 C enrichments in breath after 13 C linoleic acid administration to lactating women (Demmelmair et al, 1998) . Total recovery in breath CO 2 for lactating women was 18 ± 24%, depending on the week of lactation (Demmelmair et al, 1998) , which is comparable with our results.
In this study, about 21% of the ingested 13 C linoleic acid was recovered in breath, while the peak amount of 13 C linoleic acid in plasma was about 8%. Furthermore, a small percentage was detected as its longer chain metabolites in plasma. Since Emken et al have demonstrated that on average 92% of the linoleic acid may be absorbed (Emken et al, 1994) , a large part of the tracer is still missing. Parts of the tracer may be incorporated into membranes or stored in adipose tissue reserves. Recently, it has been demonstrated that many human tissues express D5 and D6 desaturase, of which liver, brain and heart are the most abundant (Cho et al, 1999a) . This may thus suggest that these tissues contain part of the tracer as well. Furthermore, one third of the 13 CO 2 derived from tracer oxidation may not be excreted in breath (Jones et al, 1999) . Part of the tracer may be incorporated into products of the tricarboxylic acid cycle or ®xated in the bicarbonate pool (Sidossis et al, 1995; Leijssen & Elia, 1996) .
All participants had received the same dose of 13 C18X2n-6. However, amounts of 13 C18X2n-6 and its 13 C labelled LCPs varied considerably between the subjects. In a recent similar study with 13 C a-linolenic acid (Vermunt et al, 2000) , we found a signi®cant negative correlation between plasma 13 C LCPs and the 13 C elimination with breath CO 2 . In the present study, in the three subjects of whom 13 C elimination was known, the subject with the highest amounts of 13 C LCPs had also the lowest 13 C elimination by breath and vise versa. Variation in plasma 13 C LCPs between subjects may thus, at least partly, be explained by variation in 13 C elimination by breath. Furthermore, time courses of the appearance of 13 C labelled fatty acids were C18X2n-6 for three subjects during the ®rst 12 h.
Linoleic acid metabolism in healthy subjects SHF Vermunt et al different between subjects. In the subject with the highest amounts of 13 C labelled n-6 fatty acids, time to peak amounts was the longest. Possibly, absorption of essential fatty acids andaor activity of desaturase or elongase enzymes is different from that of the other subjects.
In conclusion, a single bolus of 45 mg of 13 C18X2n-6 can be used to study the oxidation of 13 C18X2n-6. Plasma 13 C enrichments of C20X4n-6, however, were rather low and even near detection limit in some subjects. A higher dose of 13 C18X2n-6 is therefore recommended for the study of the conversion into arachidonic acid. Results of plasma total lipids and 13 CO 2 recovery in breath suggest that part of the tracer is still missing. In order to detect larger parts of the tracer, other accessible lipid fractions, like erythrocytes and possibly adipose tissue should also be included in future research. In addition, since D6 desaturation is the ratelimiting step in the conversion of linoleic and a-linolenic acid, measurement of mRNA levels of D6 desaturase, which has been sequenced recently (Cho et al, 1999b) , may help to study determinants of the n-3 and n-6 fatty acid metabolism in future research.
